Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.

Abstract

Mirabegron appears to be a promising treatment in OAB patients by shifting its management from reducing detrusor over-activity to inducing relaxation. Also it lacks the troublesome side effects associated with the standard antimuscarinic management.